Literature DB >> 1293991

Cerebral toxoplasmosis and AIDS. Clinical, neuroradiological and immunological findings in 15 patients.

G Orefice1, P B Carrieri, A Chirianni, S Rubino, G Liuzzi, G Napolitano, A Rocco.   

Abstract

Cerebral toxoplasmosis is the most common cause of focal CNS disease complicating AIDS and its incidence ranges from 3% to 40% of such patients. This opportunistic infection is generally due to reactivation of chronic toxoplasmosis as a consequence of severe immune deficiency. We present the clinical, neuroradiological and immunological findings of 15 AIDS patients with cerebral toxoplasmosis. All patients had focal neurological signs. CT-scan (13 cases) and NMR (2 cases) showed single or multiple mass lesions and edema. Serum IgG anti-Toxoplasma antibodies were positive in 14 patients; CSF specific IgG were positive in 5 out of 7 studied patients, while serum and CSF specific IgM were negative in all subjects. The intrathecal synthesis of anti-Toxoplasma antibodies were high in all 7 patients. A presumptive diagnosis of cerebral toxoplasmosis is based on the focal cerebral signs and neuroradiological findings. It is more frequently confirmed by the improvement of the clinical and neuroradiological picture during the treatment with pyrimethamine-sulphadiazine or clindamycin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293991

Source DB:  PubMed          Journal:  Acta Neurol (Napoli)        ISSN: 0001-6276


  2 in total

1.  Difficulties with diagnosis and consequential poor outcome due to stigma of acquired immunodeficiency syndrome - a case report.

Authors:  Vladimira Vuletic; Branimir Nevajda; Martina Spero; Darko Chudy
Journal:  Pathog Glob Health       Date:  2013-08-01       Impact factor: 2.894

Review 2.  Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.

Authors:  Mark P Connolly; Elizabeth Goodwin; Carina Schey; Jacqueline Zummo
Journal:  Pathog Glob Health       Date:  2017-01-16       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.